Reed and co‐workers demonstrated that EGCG was a pan‐inhibitor of the Bcl‐2 family.32 Recently, it has been shown that in several cancer cell lines (786‐O renal cell carcinoma, HNSCC, Pc‐3 and LNCaP), EGCG binds upstream of the Bcl‐2 family, resulting in downregulation of the anti‐apoptosis proteins.40 This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.